PR Newswire·Apr 29, 2026, 9:10 AM ET

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences received Patent Number 432748 from Mexico's IMPI to protect its breast cancer vaccine technology until 2040.
The new patent expands global intellectual property coverage in markets with high late-stage breast cancer diagnoses & triple-negative breast cancer incidence.
The vaccine targets human α-lactalbumin, a "retired" protein associated with lactation & aberrantly expressed in certain breast cancers.
Positive Phase 1 results demonstrated the vaccine was safe, well-tolerated, & elicited immune responses in 74% of participants across all doses.
Anixa is preparing for a Phase 2 clinical trial following the successful Phase 1 outcomes & this new patent issuance.
The technology was invented at Cleveland Clinic & exclusively licensed to Anixa Biosciences.
Dr. Amit Kumar stated the patent strengthens Anixa's ability to pursue global opportunities & partner with larger pharmaceutical companies.
Anixa's broader portfolio includes the ovarian cancer immunotherapy lira-cel & additional cancer vaccines targeting lung, colon, & prostate malignancies.